Literature DB >> 17670976

The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection.

Corrado Corti1, Giuseppe Battaglia, Gemma Molinaro, Barbara Riozzi, Anna Pittaluga, Mauro Corsi, Manolo Mugnaini, Ferdinando Nicoletti, Valeria Bruno.   

Abstract

Dual metabotropic glutamate 2/3 (mGlu2/3) receptor agonists have been examined with success in the clinic with positive proof of efficacy in several tests of anxiety and schizophrenia. Moreover, a large body of evidence has accumulated that these drugs have significant neuroprotective potential. An important discussion in the field deals with dissecting effects on mGlu2 versus effects on mGlu3 receptors, which is relevant for the potential use of subtype-selective agonists or allosteric activators. We addressed this issue using mGlu2 and mGlu3 receptor knock-out mice. We used mixed cultures of cortical cells in which astrocytes and neurons were plated at different times and could therefore originate from different mice. Cultures were challenged with NMDA for the induction of excitotoxic neuronal death. The mGlu2/3 receptor agonist, (-)-2-oxa-4-aminocyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), was equally neuroprotective in cultures containing neurons from wild-type, mGlu2-/-, or mGlu3-/- mice. Neuroprotection was instead abolished when astrocytes lacked mGlu3 receptors, unless neuronal mGlu2 receptors were also absent. The latter condition partially restored the protective activity of LY379268. Cultures in which neurons originated from mGlu2-/- mice were also intrinsically resistant to NMDA toxicity. In in vivo experiments, systemic administration of LY379268 protected striatal neurons against NMDA toxicity in wild-type and mGlu2-/- mice but not in mGlu3-/- mice. In addition, LY379268 was protective against nigrostriatal degeneration induced by low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine only in mice lacking mGlu2 receptors. We conclude that neuroprotection by mGlu2/3 receptor agonists requires the activation of astrocytic mGlu3 receptors, whereas, unexpectedly, activation of mGlu2 receptors might be harmful to neurons exposed to toxic insults.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17670976      PMCID: PMC6673047          DOI: 10.1523/JNEUROSCI.1889-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  66 in total

1.  Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795.

Authors:  A E Kingston; M J O'Neill; A Lam; K R Bales; J A Monn; D D Schoepp
Journal:  Eur J Pharmacol       Date:  1999-07-21       Impact factor: 4.432

Review 2.  Pharmacological agents acting at subtypes of metabotropic glutamate receptors.

Authors:  D D Schoepp; D E Jane; J A Monn
Journal:  Neuropharmacology       Date:  1999-10       Impact factor: 5.250

3.  A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury.

Authors:  A Ruocco; O Nicole; F Docagne; C Ali; L Chazalviel; S Komesli; F Yablonsky; S Roussel; E T MacKenzie; D Vivien; A Buisson
Journal:  J Cereb Blood Flow Metab       Date:  1999-12       Impact factor: 6.200

4.  Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes.

Authors:  R Ciccarelli; P Di Iorio; V Bruno; G Battaglia; I D'Alimonte; M D'Onofrio; F Nicoletti; F Caciagli
Journal:  Glia       Date:  1999-09       Impact factor: 7.452

5.  Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction.

Authors:  E R Matarredona; M Santiago; J L Venero; J Cano; A Machado
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

6.  Selective activation of group II mGluRs with LY354740 does not prevent neuronal excitotoxicity.

Authors:  M M Behrens; U Strasser; V Heidinger; D Lobner; S P Yu; J W McDonald; M Won; D W Choi
Journal:  Neuropharmacology       Date:  1999-10       Impact factor: 5.250

7.  Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective.

Authors:  V Bruno; I Ksiazek; G Battaglia; S Lukic; T Leonhardt; D Sauer; F Gasparini; R Kuhn; F Nicoletti; P J Flor
Journal:  Neuropharmacology       Date:  2000-09       Impact factor: 5.250

8.  Neuroprotective actions of novel and potent ligands of group I and group II metabotropic glutamate receptors.

Authors:  A E Kingston; M J O'Neill; A Bond; V Bruno; G Battaglia; F Nicoletti; J R Harris; B P Clark; J A Monn; D Lodge; D D Schoepp
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

9.  Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death.

Authors:  V Bruno; G Battaglia; I Ksiazek; H van der Putten; M V Catania; R Giuffrida; S Lukic; T Leonhardt; W Inderbitzin; F Gasparini; R Kuhn; D R Hampson; F Nicoletti; P J Flor
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

10.  LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia.

Authors:  A Bond; N Ragumoorthy; J A Monn; C A Hicks; M A Ward; D Lodge; M J O'Neill
Journal:  Neurosci Lett       Date:  1999-10-08       Impact factor: 3.046

View more
  77 in total

1.  mGlu Receptors and Cancerous Growth.

Authors:  Jessica Teh; Suzie Chen
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2011-10-25

2.  Metabotropic glutamate receptor-mediated signaling in neuroglia.

Authors:  David J Loane; Bogdan A Stoica; Alan I Faden
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-01-11

3.  Activation of group II metabotropic glutamate receptors induces long-term depression of excitatory synaptic transmission in the substantia nigra pars reticulata.

Authors:  Kari A Johnson; Colleen M Niswender; P Jeffrey Conn; Zixiu Xiang
Journal:  Neurosci Lett       Date:  2011-09-16       Impact factor: 3.046

Review 4.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

5.  The individual and combined effects of phenmetrazine and mgluR2/3 agonist LY379268 on the motivation to self-administer cocaine.

Authors:  Anushree N Karkhanis; Thomas J R Beveridge; Bruce E Blough; Sara R Jones; Mark J Ferris
Journal:  Drug Alcohol Depend       Date:  2016-06-25       Impact factor: 4.492

Review 6.  Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Authors:  Meng-Lin Li; Xi-Quan Hu; Feng Li; Wen-Jun Gao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-24       Impact factor: 5.067

7.  Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin.

Authors:  G Martella; P Platania; D Vita; G Sciamanna; D Cuomo; A Tassone; A Tscherter; T Kitada; P Bonsi; J Shen; A Pisani
Journal:  Exp Neurol       Date:  2008-11-21       Impact factor: 5.330

Review 8.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 9.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 10.  The role of glutamate and the immune system in organophosphate-induced CNS damage.

Authors:  Arik Eisenkraft; Avshalom Falk; Arseny Finkelstein
Journal:  Neurotox Res       Date:  2013-03-27       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.